KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Non-cash Items (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 15 years of Non-cash Items data on record, last reported at $79.3 million in Q4 2025.

  • For Q4 2025, Non-cash Items rose 1032.92% year-over-year to $79.3 million; the TTM value through Dec 2025 reached $79.3 million, up 1032.92%, while the annual FY2025 figure was $79.3 million, 1032.92% up from the prior year.
  • Non-cash Items reached $79.3 million in Q4 2025 per ACAD's latest filing, up from $7.0 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $91.0 million in Q4 2023 and bottomed at $1.1 million in Q4 2022.
  • Average Non-cash Items over 5 years is $38.9 million, with a median of $16.4 million recorded in 2021.
  • Peak YoY movement for Non-cash Items: plummeted 93.59% in 2022, then skyrocketed 8546.58% in 2023.
  • A 5-year view of Non-cash Items shows it stood at $16.4 million in 2021, then tumbled by 93.59% to $1.1 million in 2022, then surged by 8546.58% to $91.0 million in 2023, then plummeted by 92.31% to $7.0 million in 2024, then soared by 1032.92% to $79.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $79.3 million in Q4 2025, $7.0 million in Q4 2024, and $91.0 million in Q4 2023.